194.30
+1.5(+0.78%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
1017
First IPO Date
January 28, 2015
| Name | Title | Pay | Year Born |
| Mr. Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director | 0 | 1960 |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | 0 | 1961 |
| Mr. Scott T. Smith | Chief Financial Officer, Executive Vice President & Member of Executive Board | 0 | 1974 |
| Ms. Pedersen Anni Lotte Kirstine Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board | 0 | 1961 |
| Mr. Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer & Member of the Executive Board | 0 | 1971 |
| Dr. Kennett Sprogoe Ph.D. | Executive Vice President and Head of Research & Product Development | 0 | 1979 |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President & Head of Clinical Development for Oncology | 0 | 1974 |
| Ms. Sherrie Glass | Chief Business Officer | 0 | N/A |
| Mr. Mads Bodenhoff | Senior Vice President, Head of Finance & Principal Accounting Officer | 0 | 1969 |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | 0 | 1969 |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.